STOCK TITAN

Poplar Point cuts NovaBay (NBY) ownership below 5% reporting level

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Poplar Point Capital Management LLC and related reporting persons report beneficial ownership of 1,020,300 shares of NovaBay Pharmaceuticals common stock, representing 0.81% of the outstanding shares. The filing notes that NovaBay issued additional shares after a vote of security holders, which reduced the group’s stake below the 5% Schedule 13D reporting threshold.

The shares are held through Poplar Point Capital Management, Poplar Point Capital Partners, Poplar Point Capital GP and Jad Fakhry, who share voting and dispositive power over the position. The reporting persons state there have been no recent acquisitions or dispositions, but as of the effective date they intend to begin disposing of their NovaBay common stock.

Positive

  • None.

Negative

  • None.





Jad Fakhry
330 Primrose Road, Suite 400
Burlingame, CA, 94010
650-239-9049

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
10/20/2025

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Poplar Point Capital Management LLC
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry, Manager
Date:03/11/2026
Poplar Point Capital Partners LP
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry, Manager
Date:03/11/2026
Poplar Point Capital GP LLC
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry, Manager
Date:03/11/2026
Jad Fakhry
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry
Date:03/11/2026

FAQ

What ownership stake in NovaBay Pharmaceuticals (NBY) does Poplar Point report in this Schedule 13D/A?

Poplar Point and related reporting persons report owning 1,020,300 shares, or 0.81% of NovaBay’s common stock. This reflects their current beneficial ownership after NovaBay issued additional shares that diluted their percentage below the 5% reporting threshold.

Why did Poplar Point file Amendment No. 3 to its Schedule 13D on NovaBay (NBY)?

The amendment discloses that NovaBay’s issuance of additional shares reduced Poplar Point’s stake below 5%. Following a vote of security holders, NovaBay issued more common stock, which lowered the reporting persons’ ownership percentage to 0.81% of the outstanding shares.

Does Poplar Point plan to sell its NovaBay (NBY) shares according to this filing?

The reporting persons state they will begin disposing of their NovaBay common stock as of the effective date. They also note there have been no recent acquisitions or dispositions in the 60 days prior to the filing’s effective date.

Who are the reporting persons in the NovaBay (NBY) Schedule 13D/A amendment?

The reporting group includes Poplar Point Capital Management LLC, Poplar Point Capital Partners LP, Poplar Point Capital GP LLC and Jad Fakhry. Poplar Point entities are Delaware entities, and Jad Fakhry is a United States citizen who controls the Poplar Point entities.

How much voting power does Poplar Point have over NovaBay (NBY) shares in this filing?

The reporting persons report shared voting power over 1,020,300 NovaBay shares and no sole voting power. They also report shared dispositive power over the same 1,020,300 shares, indicating coordinated control over the entire disclosed position.

Did Poplar Point report any recent NovaBay (NBY) trades in the 60 days before this filing?

The filing states there were no applicable transactions in the 60 days before the effective date. The reporting persons describe their NovaBay activity as having no recent acquisitions or dispositions during that period, with the change in percentage due to new shares issued by NovaBay.
Novabay Pharma

NYSE:NBY

View NBY Stock Overview

NBY Rankings

NBY Latest News

NBY Latest SEC Filings

NBY Stock Data

32.92M
2.12M
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE